On October 11, 2018, Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Proteus Digital Health (Proteus) announced they had signed a five-year expanded global collaboration agreement to further development and commercialization of a portfolio of medicines including the ABILIFY MYCITE® (aripiprazole tablets with sensor). As part of the expanded collaboration, Otsuka made $88 million in related equity and other payments to Proteus. A collaborative team comprised of Otsuka and Proteus employees will be dedicated to commercial development and market coordination for the ABILIFY MYCITE System, software integration and standardization, manufacturing and supply chain integration, and coordination. This includes the joint development . . .